[May 29, 2017]

Global Chimeric Antigen Receptor (CAR) T cell Immunotherapy Competitive Landscape, Pipeline and Market Analysis 2017 - Research and Markets

Research and Markets has announced the addition of the "Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis - 2017" report to their offering.

The Report covers the 68 companies, which are active in this field including 29 leading companies with 123 products targeting 44 different antigens and 16 different technologies.

The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis.

Reports Highlights:

• CAR-T cell Therapy Pipeline scenario
• Collaborations & partnering deals
• Current Prominent Research Areas and Key Players
• Pipeline product profiles CAR-T Technologies and Targeted Antigens
• Licensing opportunities
• Market Drivers and Barriers

Key Topics Covered:

1. Report Introduction
2. Executive Summary Snapshot
3. Executive Summary
4. Introduction
5. Chimeric antigen receptor (CAR) T-cells
6. History
7. CARs and Generations
8. Advantages of CAR-T cells
9. Adverse Events with CAR T-cell Terapy
10. Limitations of Existing Technologies for CAR T-Cells
11. CAR-T Cell Therapy-Analysis
12. CAR-T Collaboration Deals
13. CAR-T Cells Therapy Collaborations and Deal Year
14. Collaborations & Deal Value Trends
15. Companies collaborations for future developments
16. CAR-T Acquisitions Deals
17. CAR-T Cells Therapy Acquisitions Trends
18. CAR-T Cells Therapy Acquisitions Offerings by Big Giants
19. New facilityfor the development of CAR-T cells
20. JCAR015: Major Set Back for Juno Therapeutics
21. CAR-T Licensing Opportunities
22. Pipeline Scenario
23. Pipeline Products under Development-An Overview
24. Pipeline Products under Development by Company
25. CAR T-cells Therapeutic Areas & Companies
26. CAR-T cells Targeted Antigens
27. CAR-T Therapies-Clinical trials & Completion Year
28. CAR T-cell Technologies & Companies Involved
29. CAR-T Safety Switches & Company involved
30. Companies with Upcoming CAR-T Therapeutics
    
    
    
    

• Arbele Limited
• Apceth
• Aurora Biopharma
• Autolus Limited
• Avacta Life Sciences Limited
• Beijing Biohealthcare Biotechnology Co.,Ltd
• Beijing Doing Biomedical Co., Ltd.
• Beijing Sanwater Biological Technology Co., Ltd.
• Bellicum Pharmaceuticals Inc.
• Benitec Biopharma Limited
• BioAtla, LLC
• BioInvent International
• Bluebird bio
• CARMA Therapeutics
• Cytomx Therapeutics
• Enlivex Therapeutics Ltd
• Eureka Therapeutics, Inc
• Fate Therapeutics
• Formula Pharmaceuticals
• GlaxoSmithKline plc
• Mustang Bio ( Subsidiary of Fortress Biotech)
• Nohla Therapeutics Inc.
• Novartis Pharmaceuticals
• OncoTAb, Inc.
• Oncternal Therapeutics, Inc
• Regen BioPharma, Inc.
• Shanghai GeneChem Co., Ltd.
• Shire plc
• Sinobioway Cell Therapy Co., Ltd.
• Sirtex Medical
• Sorrento Therapeutics
• SymVivo
• Takara Bio
• Tessa Therapeutics Pte Ltd.
• The Beijing Pregene Science and Technology Company, Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/btqb5l/chimeric_antigen

View source version on businesswire.com: http://www.businesswire.com/news/home/20170529005074/en/

[ Back To TMCnet.com's Homepage ]